Home » Stocks » CBMG

Cellular Biomedicine Group, Inc. (CBMG)

Stock Price: $18.11 USD 0.00 (0.00%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
After-hours: $18.19 +0.08 (0.44%) Jan 15, 4:34 PM
Market Cap 352.75M
Revenue (ttm) 322,950
Net Income (ttm) -54.80M
Shares Out 19.43M
EPS (ttm) -2.83
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $18.11
Previous Close $18.11
Change ($) 0.00
Change (%) 0.00%
Day's Open 17.77
Day's Range 17.76 - 18.15
Day's Volume 21,747
52-Week Range 11.51 - 19.27

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
PRNewsWire - 1 month ago

NEW YORK, Dec. 17, 2020 /PRNewswire/ -- Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection w...

PRNewsWire - 1 month ago

GAITHERSBURG, Md. and SHANGHAI, Dec. 4, 2020 /PRNewswire/ -- Cellular Biomedicine Group Inc. (NASDAQ: CBMG) ("CBMG" or the "Company"), a biopharmaceutical firm engaged in the drug development ...

PRNewsWire - 2 months ago

GAITHERSBURG, Md. and SHANGHAI, Nov. 9, 2020 /PRNewswire/ -- Cellular Biomedicine Group Inc. (NASDAQ: CBMG) ("CBMG" or the "Company"), a biopharmaceutical firm engaged in the drug development ...

Seeking Alpha - 2 months ago

CBMG agreed to be taken private at $19.75 per share in cash. The transaction is subject to shareholder approval as well as CFIUS clearance.

PRNewsWire - 3 months ago

NEW YORK, Oct. 5, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, is investigating: Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) concerning potential violations of...

Business Wire - 4 months ago

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating: Rosetta Stone Inc. (NYSE: RST) concerning potential violations of the federal securities laws ...

PRNewsWire - 4 months ago

NEW YORK, Aug. 20, 2020 /PRNewswire/ -- Cellular Biomedicine Group, Inc.

PRNewsWire - 5 months ago

PHILADELPHIA, Aug. 14, 2020 /PRNewswire/ -- Kaskela Law LLC announces that it is investigating Cellular Biomedicine Group, Inc.

Business Wire - 5 months ago

NEW YORK--(BUSINESS WIRE)--Rowley Law PLLC is investigating potential securities law violations by Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) and its board of directors concerning the pro...

PRNewsWire - 5 months ago

NEW YORK, Aug. 12, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Cellular Biomedicine Group, Inc.

Business Wire - 5 months ago

NEW YORK--(BUSINESS WIRE)-- #Acquisition--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of Cell...

PRNewsWire - 5 months ago

GAITHERSBURG, Md. and SHANGHAI, Aug.

Newsfile Corp - 5 months ago

New York, New York--(Newsfile Corp. - August 12, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All Persons or Entities who purchased Cellular Biomedicine Group,...

PRNewsWire - 5 months ago

GAITHERSBURG, Md. and SHANGHAI, Aug.

PRNewsWire - 6 months ago

GAITHERSBURG, Md. and SHANGHAI, July 13, 2020 /PRNewswire/ -- Cellular Biomedicine Group, Inc. (Nasdaq: CBMG) ("CBMG" or the "Company"), a biopharmaceutical firm engaged in the drug developmen...

PRNewsWire - 6 months ago

GAITHERSBURG, Md. and SHANGHAI, June 30, 2020 /PRNewswire/ -- Cellular Biomedicine Group, Inc. (Nasdaq: CBMG) ("CBMG" or the "Company"), a biopharmaceutical firm engaged in the drug developmen...

PRNewsWire - 6 months ago

GAITHERSBURG, Md. and SHANGHAI, June 29, 2020 /PRNewswire/ -- Cellular Biomedicine Group Inc. (Nasdaq: CBMG) ("CBMG" or the "Company"), a biopharmaceutical firm engaged in the drug development...

Seeking Alpha - 8 months ago

Cellular Biomedicine Group, Inc. (CBMG) CEO Tony Liu on Q1 2020 Results - Earnings Call Transcript

Seeking Alpha - 10 months ago

Cellular Biomedicine Group's (CBMG) CEO Tony Liu on Q4 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

Cellular Biomedicine Group, Inc. (CBMG) CEO Tony Liu on Q3 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

Cellular Biomedicine Group, Inc. (CBMG) CEO Bizuo Liu on Q2 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

Cellular Biomedicine Group, Inc. (CBMG) CEO Tony Liu on Q1 2019 Results - Earnings Call Transcript

About CBMG

Cellular Biomedicine Group, a clinical stage biopharmaceutical company, develops immunotherapies for cancer and stem cell therapies for degenerative diseases in Greater China. The company develops treatments utilizing proprietary cell based technologies, including immune cell therapy for treating a range of cancer indications comprising technologies in chimeric antigen receptor modified T cells (CAR-T), T-cells with genetically modified, tumor antigen-specific T-cell receptors, and next generation neoantigen-reactive bio-markers based tumor inf... [Read more...]

Industry
Biotechnology
CEO
Tony Liu
Employees
217
Stock Exchange
NASDAQ
Ticker Symbol
CBMG
Full Company Profile

Financial Performance

In 2019, CBMG's revenue was $339,920, an increase of 51.48% compared to the previous year's $224,403. Losses were -$49.98 million, 28.3% more than in 2018.

Financial Statements

Analyst Forecasts

According to one analyst, the rating for CBMG stock is "Hold" and the 12-month stock price forecast is 19.00.

Price Target
$19.00
Analyst Consensus: Hold